UC Berkeley waters down DNA testing
By Victoria Colliver,
San Francisco Chronicle
| 08. 13. 2010
[Quotes CGS's Jesse Reynolds]
Under pressure from state public health officials, the professors behind UC Berkeley's controversial plan to genetically test incoming freshmen and transfer students said Thursday they will scale back the program so that participants will not receive personal results from their DNA samples.
The university raised the ire of genetic watchdog and privacy groups in May when it first launched "Bring Your Genes to Cal." The voluntary program is believed to be the largest genetic testing project at a U.S. university.
The 5,500 incoming freshman and transfer students for the fall semester received testing kits in the mail and were asked to submit cheek swabs of their DNA to kick off a yearly exercise to involve the new students in a common educational experience centered on a theme. This year's theme is personalized medicine.
Students were to receive personal information about three of their genes - those related to the ability to break down lactose, metabolize alcohol and absorb folates. This information was to be the basis of lectures and discussions on such topics as the ethical, social and legal interpretations...
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 09.08.2026
It is one of biology’s most ingenious rhythms: Every baby is born young. No matter how much wear and tear their parents’ DNA accumulated over their lifetimes, reproduction erases the molecular scars, handing a clean slate to the next generation...
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Jessica Hamzelou, MIT Technology Review | 07.23.2026
When it comes to organ donation, time is everything. As soon as an organ has been carefully removed from a donor’s body, it starts to deteriorate. Surgeons have a matter of hours to get it into a recipient. Leave...